Whole Exome Sequencing Market Report 2026

The whole exome sequencing market size has grown exponentially in recent years. It will grow from $3.36 billion in 2025 to $4.06 billion in 2026 at a compound annual growth rate (CAGR) of 21%. The growth in the historic period can be attributed to increasing availability of next-generation sequencing platforms, growth in genetic disorder diagnosis, expansion of academic genomic research, declining sequencing costs, rising adoption in clinical laboratories.

The whole exome sequencing market size is expected to see exponential growth in the next few years. It will grow to $8.87 billion in 2030 at a compound annual growth rate (CAGR) of 21.5%. The growth in the forecast period can be attributed to increasing demand for precision diagnostics, expansion of genomic medicine programs, growing integration of sequencing data into clinical decision-making, rising investments in sequencing infrastructure, increasing adoption in drug discovery. Major trends in the forecast period include increasing adoption of exome-based diagnostic testing, rising use of sequencing in rare disease detection, growing integration of bioinformatics analysis platforms, expansion of personalized medicine applications, enhanced focus on cost-effective sequencing workflows.

The rising prevalence of HIV (human immunodeficiency virus) is expected to drive the growth of the whole exome sequencing market in the coming years. HIV is a virus that attacks the body’s immune system. Whole exome sequencing provides detailed genomic information of viruses, which is useful for designing personalized treatments and vaccines for HIV. For example, in August 2024, according to the Minority HIV/AIDS Fund (MHAF), a US-based government agency, approximately 39.9 million individuals worldwide were living with HIV in 2023, including 38.6 million adults and 1.4 million children, reflecting an increase compared to previous years. Therefore, the rising prevalence of HIV is fueling growth in the whole exome sequencing market.

Key companies in the whole exome sequencing market are developing advanced next-generation sequencing (NGS) ultra-fast technology to improve the speed and accuracy of genetic analysis, enabling faster diagnostics and personalized treatment plans. NGS ultra-fast technology enhances whole exome sequencing by rapidly analyzing exonic regions, allowing quick detection of genetic mutations critical for diagnosis and research. For instance, in January 2023, Qiagen, a Germany-based medical devices and healthcare company, launched the CLC Genomics Workbench Premium with LightSpeed technology, which enables efficient analysis of whole genome sequencing (WGS) and whole exome sequencing (WES) data. This innovation can process an entire genome in just 25 minutes for about $1 using cloud computing, while also supporting local hardware, reducing both time and costs and improving accessibility for large-scale genetic testing in the WES market.

In February 2023, NIMGenetics Genómica y Medicina S.L., a Spain-based biotechnology company specializing in human genetic diagnostics, acquired Gene Predictis, S.A. for an undisclosed amount. Through this acquisition, NIMGenetics aims to expand its presence in Central European markets and strengthen its position in the European genetic diagnostics sector by combining both companies’ genomic service portfolios and customer bases. Gene Predictis S.A., a Switzerland-based diagnostic company, specializes in preventive health and precision medicine, offering proprietary algorithms and diagnostic tools in areas including genetics, pharmacogenomics, microbiology, and epidemiology.

Major companies operating in the whole exome sequencing market are Thermo Fisher Scientific Inc., Illumina Inc., Eurofins Genomics, Azenta US Inc., CD Genomics, Psomagen Inc., Agilent Technologies, BGI Genomics, F. Hoffmann-La Roche Ltd., QIAGEN Inc., Macrogen Inc., Ambry Genetics, Bio-Rad Laboratories Inc., Bioneer Corporation, Foundation Medicine Inc., Otogenetics Corporation, Geneyx Genomex Ltd., ArcherDX Inc., Blueprint Genetics Oy, Centogene AG, Fulgent Genetics Inc., Natera Inc., GeneDx Inc., GENEWIZ Inc., Novogene Corporation, PerkinElmer Inc., Personalis Inc.

North America was the largest region in the whole exome sequencing market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global whole exome sequencing market report during the forecast period. The regions covered in the whole exome sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the whole exome sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the whole exome sequencing market by increasing costs of imported sequencing instruments, reagents, enrichment kits, and data processing hardware. Clinical laboratories and research institutes in North America and Europe are most affected due to dependence on imported sequencing platforms, while Asia-Pacific faces higher costs for equipment exports. These tariffs are increasing testing expenses and limiting scalability. However, they are also supporting local reagent manufacturing, regional sequencing service providers, and domestic bioinformatics development.

The whole exome sequencing market research report is one of a series of new reports that provides whole exome sequencing market statistics, including whole exome sequencing industry global market size, regional shares, competitors with a whole exome sequencing market share, detailed whole exome sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the whole exome sequencing industry. This whole exome sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Whole exome sequencing is a genomic sequencing technique in which all protein-coding regions of a genome are analyzed. It is commonly used in laboratories to identify mutations that may be responsible for specific diseases.

The primary products of whole exome sequencing are systems, kits, and services. Systems involve the examination of interactions and behaviors of biological elements such as molecules, cells, and organs. The technologies employed include sequencing by synthesis, ion semiconductor sequencing, and others, which are used for applications in diagnostics, drug discovery and development, personalized medicine, agriculture, and animal research. These products are utilized by hospitals and clinics, pharmaceutical and biotechnology companies, academic and research institutions, clinical laboratories, and other end users.

The whole exome sequencing market consists of revenues earned by entities by providing services such as exome capture, library construction, deep sequencing, raw data quality control, and bioinformatics analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The whole exome sequencing market also includes sales of instruments, comparison tools, and sequencing reagents which are used in providing whole exome sequencing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.